Role of photodynamic therapy using talaporfin sodium and a semiconductor laser in patients with newly diagnosed glioblastoma

Restricted access

OBJECTIVE

In this study on the effectiveness and safety of photodynamic therapy (PDT) using talaporfin sodium and a semiconductor laser, the long-term follow-up results of 11 patients with glioblastoma enrolled in the authors’ previous phase II clinical trial (March 2009–2012) and the clinical results of 19 consecutive patients with newly diagnosed glioblastoma prospectively enrolled in a postmarket surveillance (March 2014–December 2016) were analyzed and compared with those of 164 patients treated without PDT during the same period.

METHODS

The main outcome measures were the median overall survival (OS) and progression-free survival (PFS) times. Moreover, the adverse events and radiological changes after PDT, as well as the patterns of recurrence, were analyzed and compared between the groups. Kaplan-Meier curves were created to assess the differences in OS and PFS between the groups. Univariate and multivariate analyses were performed to identify the prognostic factors, including PDT, among patients with newly diagnosed glioblastoma.

RESULTS

The median PFS times of the PDT and control groups were 19.6 and 9.0 months, with 6-month PFS rates of 86.3% and 64.9%, respectively (p = 0.016). The median OS times were 27.4 and 22.1 months, with 1-year OS rates of 95.7% and 72.5%, respectively (p = 0.0327). Multivariate analyses found PDT, preoperative Karnofsky Performance Scale score, and IDH mutation to be significant independent prognostic factors for both OS and PFS. Eighteen of 30 patients in the PDT group experienced tumor recurrence, including local recurrence, distant recurrence, and dissemination in 10, 3, and 4 patients, respectively. Conversely, 141 of 164 patients in the control group experienced tumor recurrence, including 101 cases of local recurrence. The rate of local recurrence tended to be lower in the PDT group (p = 0.06).

CONCLUSIONS

The results of the present study suggest that PDT with talaporfin sodium and a semiconductor laser provides excellent local control, with few adverse effects even in cases of multiple laser irradiations, as well as potential survival benefits for patients with newly diagnosed glioblastoma.

ABBREVIATIONS CTCAE = Common Terminology Criteria for Adverse Events; KPS = Karnofsky Performance Scale; MGMT = O-6-methylguanine-DNA methyltransferase; OS = overall survival; PDT = photodynamic therapy; PFS = progression-free survival.
Article Information

Contributor Notes

Correspondence Yoshihiro Muragaki: Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan. ymuragaki@twmu.ac.jp.INCLUDE WHEN CITING Published online December 7, 2018; DOI: 10.3171/2018.7.JNS18422.Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Headings
References
  • 1

    Akimoto J: Photodynamic therapy for malignant brain tumors. Neurol Med Chir (Tokyo) 56:1511572016

  • 2

    Akimoto JHaraoka JAizawa K: Preliminary clinical report on safety and efficacy of photodynamic therapy using talaporfin sodium for malignant gliomas. Photodiagn Photodyn Ther 9:91992012

    • Search Google Scholar
    • Export Citation
  • 3

    Beck TJKreth FWBeyer WMehrkens JHObermeier AStepp H: Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 39:3863932007

    • Search Google Scholar
    • Export Citation
  • 4

    Castano APMroz PHamblin MR: Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6:5355452006

  • 5

    Dolmans DEFukumura DJain RK: Photodynamic therapy for cancer. Nat Rev Cancer 3:3803872003

  • 6

    Fukui AMuragaki YSaito TMaruyama TNitta MIkuta S: Volumetric analysis using low-field intraoperative magnetic resonance imaging for 168 newly diagnosed supratentorial glioblastomas: effects of extent of resection and residual tumor volume on survival and recurrence. World Neurosurg 98:73802017

    • Search Google Scholar
    • Export Citation
  • 7

    Kato HFurukawa KSato MOkunaka TKusunoki YKawahara M: Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer 42:1031112003

    • Search Google Scholar
    • Export Citation
  • 8

    Konishi YMuragaki YIseki HMitsuhashi NOkada Y: Patterns of intracranial glioblastoma recurrence after aggressive surgical resection and adjuvant management: retrospective analysis of 43 cases. Neurol Med Chir (Tokyo) 52:5775862012

    • Search Google Scholar
    • Export Citation
  • 9

    Li YMSuki DHess KSawaya R: The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? J Neurosurg 124:9779882016

    • Search Google Scholar
    • Export Citation
  • 10

    Louis DNOhgaki HWiestler ODCavenee WKBurger PCJouvet A: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:971092007

    • Search Google Scholar
    • Export Citation
  • 11

    Mimura SIto YNagayo TIchii MKato HSakai H: Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer. Lasers Surg Med 19:1681721996

    • Search Google Scholar
    • Export Citation
  • 12

    Moan JBerg K: The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53:5495531991

    • Search Google Scholar
    • Export Citation
  • 13

    Mroz PHashmi JTHuang YYLange NHamblin MR: Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol 7:75912011

    • Search Google Scholar
    • Export Citation
  • 14

    Muragaki YAkimoto JMaruyama TIseki HIkuta SNitta M: Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. J Neurosurg 119:8458522013

    • Search Google Scholar
    • Export Citation
  • 15

    Murakami RHirai TNakamura HFurusawa MNakaguchi YUetani H: Recurrence patterns of glioblastoma treated with postoperative radiation therapy: relationship between extent of resection and progression-free interval. Jpn J Radiol 30:1931972012

    • Search Google Scholar
    • Export Citation
  • 16

    Muroya TKawasaki KSuehiro YKunugi TUmayahara KAkiya T: Application of PDT for uterine cervical cancer. Diagn Ther Endosc 5:1831901999

    • Search Google Scholar
    • Export Citation
  • 17

    Quirk BJBrandal GDonlon SVera JCMang TSFoy AB: Photodynamic therapy (PDT) for malignant brain tumors—where do we stand? Photodiagn Photodyn Ther 12:5305442015

    • Search Google Scholar
    • Export Citation
  • 18

    Sanai NPolley MYMcDermott MWParsa ATBerger MS: An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:382011

    • Search Google Scholar
    • Export Citation
  • 19

    Senft CBink AFranz KVatter HGasser TSeifert V: Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 12:99710032011

    • Search Google Scholar
    • Export Citation
  • 20

    Stummer WBeck TBeyer WMehrkens JHObermeier AEtminan N: Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. J Neurooncol 87:1031092008

    • Search Google Scholar
    • Export Citation
  • 21

    Stupp RMason WPvan den Bent MJWeller MFisher BTaphoorn MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:9879962005

    • Search Google Scholar
    • Export Citation
  • 22

    Stylli SSKaye AH: Photodynamic therapy of cerebral glioma—a review Part I—a biological basis. J Clin Neurosci 13:6156252006

  • 23

    Stylli SSKaye AHMacGregor LHowes MRajendra P: Photodynamic therapy of high grade glioma—long term survival. J Clin Neurosci 12:3893982005

    • Search Google Scholar
    • Export Citation
  • 24

    Tetard MCVermandel MLeroy HALeroux BMaurage CALejeune JP: Interstitial 5-ALA photodynamic therapy and glioblastoma: Preclinical model development and preliminary results. Photodiagn Photodyn Ther 13:2182242016

    • Search Google Scholar
    • Export Citation
  • 25

    Tsurubuchi TZaboronok AYamamoto TNakai KYoshida FShirakawa M: The optimization of fluorescence imaging of brain tumor tissue differentiated from brain edema—in vivo kinetic study of 5-aminolevulinic acid and talaporfin sodium. Photodiagn Photodyn Ther 6:19272009

    • Search Google Scholar
    • Export Citation
  • 26

    Usuda JIchinose SIshizumi THayashi HOhtani KMaehara S: Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0 cm in diameter. Clin Cancer Res 16:219822042010

    • Search Google Scholar
    • Export Citation
  • 27

    Wen PYMacdonald DRReardon DACloughesy TFSorensen AGGalanis E: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:196319722010

    • Search Google Scholar
    • Export Citation
  • 28

    Yano TKasai HHorimatsu TYoshimura KTeramukai SMorita S: A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget 8:22135221442017

    • Search Google Scholar
    • Export Citation
TrendMD
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 131 131 131
Full Text Views 45 45 45
PDF Downloads 54 54 54
EPUB Downloads 0 0 0
PubMed
Google Scholar